Limited genetic impact

Pharmacogenomic information on the OneOme RightMed® test cannot be used to inform a prescription decision in two situations:

  • blue indicator icon   LIMITED GENETIC IMPACT >
    • ●    No clinically relevant genetic variants are known to impact medication
  • grey indicator icon   OTHER MEDICATIONS >
    • ●    Medication that has not met criteria for inclusion on the RightMed test or medication that has shown to be significantly affected by gene variant(s) not included on the RightMed test

These medications are available for the provider to review in our online RightMed Advisor, which provides information on their classification and can be evaluated for drug-to-drug interactions.

LIMITED GENETIC IMPACT

The genes tested on the RightMed pharmacogenomic test will not yield meaningful information for these medications because these medications have been shown to be unaffected by any known, clinically relevant genetic variants. They are included in the RightMed Advisor in the limited genetic impact category. They are binned into a blue category and indicated by indicator icon.

By providing information on these drugs, OneOme helps providers make a more informed decision even if these medications are not dependent on the patient’s genotype.

This saves you, as the provider, time, expertise, and the resources necessary for evaluating the available pharmacogenomic information on these medications by analyzing and compiling the available clinical literature.

Allergy
Desloratadine
Phenylephrine
Analgesic/Anesthesiology
Dexmedetomidine
Hydromorphone
Naloxone
Naltrexone
Anticoagulant/Antiplatelet
Dalteparin
Enoxaparin
Heparin
Prasugrel
Tirofiban
Antidote
Sodium nitrite testtube icon
Succimer
Cardiovascular
Alirocumab
Atenolol
Benazepril
Chlorthalidone
Colesevelam
Digoxin
Enalapril
Ezetimibe
Fenofibric acid
Fosinopril
Furosemide
Gemfibrozil
Hydrochlorothiazide
Lisinopril
Nitroglycerin
Perindopril
Ramipril
Rosuvastatin
Sotalol
Spironolactone
Telmisartan
Endocrinology
Exenatide
Ibandronate
Insulin aspart
Insulin aspart protamine/Insulin aspart
Insulin aspart/Insulin degludec
Insulin degludec
Insulin detemir
Insulin glargine
Insulin glulisine
Insulin lispro
Insulin lispro protamine/Insulin lispro
Insulin NPH
Insulin NPH/Insulin regular
Insulin regular
Insulin regular (oral inhalation)
Levothyroxine
Metformin
Pamidronate
Propylthiouracil
Risedronate
Vasopressin
Gastroenterology
Adalimumab
Certolizumab pegol
Infliximab
Genetic disease
Sapropterin
Sodium phenylbutyrate
Velaglucerase alfa testtube icon
Hematology
Darbepoetin alfa
Decitabine
Epoetin alfa
Immunosuppression
Mycophenolate
Infectious disease
Atovaquone
Cefdinir
Ceftriaxone
Fluconazole
Flucytosine
Levofloxacin
Meropenem
Moxifloxacin
Nitrofurantoin testtube icon
Nystatin
Piperacillin
Posaconazole
Ribavirin
Sofosbuvir
Sulfadiazine testtube icon
Vancomycin
Zanamivir
Neurology
Gabapentin
Interferon beta-1a
Interferon beta-1b
Levetiracetam
Memantine
Pramipexole
Pregabalin
Rivastigmine
Vigabatrin
Oncology
Afatinib testtube icon
Alemtuzumab testtube icon
Asparaginase
Bevacizumab
Bleomycin
Carboplatin
Cetuximab testtube icon
Fulvestrant testtube icon
Ibritumomab testtube icon
Lenalidomide testtube icon
Leucovorin calcium
Obinutuzumab testtube icon
Ofatumumab testtube icon
Oxaliplatin
Panitumumab testtube icon
Pemetrexed
Pertuzumab testtube icon
Rituximab testtube icon
Temozolomide
Thalidomide
Trastuzumab testtube icon
Psychiatry
Desvenlafaxine
Lithium
Milnacipran
Paliperidone
Varenicline
Pulmonary
Albuterol
Levalbuterol
Montelukast
Tiotropium
Rheumatology
Belimumab
Etanercept
Probenecid testtube icon
Sleep medicine
Temazepam



ADDITIONAL TESTING

test tube icon : According to the FDA drug label, additional laboratory testing may be indicated.

Other medications

These medications have not met criteria for inclusion on the RightMed test or have shown to be significantly affected by genetic variant(s) not included on the RightMed test. These medications are included in the pharmacogenomics database in the Other medications category. They are binned into a gray category and indicated by gray med icon.

As OneOme continuously reviews medications, information on their metabolism will regularly been added to the pharmacogenomics database. OneOme strives to provide relevant information that empowers providers in their therapeutic decision.